Intismeran autogene improves RFS and DMFS in resected melanoma, Merck says

What happened

Merck said on 13 October 2026 that it will present the first Phase 3 results for intismeran autogene, the personalized neoantigen mRNA vaccine it is developing with Moderna, given with Keytruda, at the ESMO 2026 Presidential Symposium ^[1]. The INTerpath-001 data show improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda alone in patients with completely resected stage IIB-IV melanoma treated in the adjuvant setting ^[1]. Moderna's 30 September 2026 SEC filing goes further on strategy, describing positive Phase 3 results and saying the company is preparing for a potential launch and scale-up ^[4]. The two companies co-develop the vaccine, with Merck's MSD holding rights outside the US and Canada ^[4].

Why it matters

Adjuvant melanoma after complete resection is already Keytruda's ground: the checkpoint inhibitor is FDA-labeled for adjuvant treatment of resected stage IIB, IIC or III melanoma ^[6]. INTerpath-001 asks whether adding a patient-specific vaccine to that same backbone cuts recurrence below what the checkpoint inhibitor achieves alone.

Who is exposed

Bristol Myers Squibb's melanoma franchise sits closest. Its PD-1 agent Opdivo and the PD-1/LAG-3 pairing Opdualag are FDA-labeled for unresectable or metastatic melanoma ^[7][8]. A vaccine-plus-checkpoint regimen that stretches recurrence-free survival in resected patients raises the question every PD-1/LAG-3 asset will face: can a single-agent or dual-checkpoint approach match a combination that adds a personalized vaccine? The pressure lands on the whole class.

What Prognyx could not verify

No hazard ratios, percentage differences or p-values for INTerpath-001 are available as of this briefing; the companies have said the trial met its endpoints and showed improvements, without quantifying them. Safety and tolerability for the combination do not appear in the public record here, and neither does any FDA or EMA filing timeline. The registry adds a wrinkle: NCT05933577 still lists INTerpath-001 as active and no longer recruiting, carries a primary completion date of 26 October 2029 and shows no posted results, leaving the public registry a step behind the reported topline ^[2].

What to watch next

• The full data at the ESMO 2026 Presidential Symposium: effect size and safety, the two things the topline statement leaves open ^[1].
• A registry update for NCT05933577, which today still points to a 26 October 2029 primary completion with no results posted ^[2].
• A separate Phase 3 program Moderna initiated in high-risk stage 1 non-small cell lung cancer, testing intismeran autogene alone and with Keytruda QLEX, per its Q1 2026 filing ^[5].

The now-what

Three moves for a melanoma or vaccine developer. First, treat the adjuvant bar as moving and model recurrence-free survival as the endpoint a next program has to beat, not match. Second, watch the manufacturing question: personalized neoantigen vaccines need per-patient production, and Moderna's launch-prep language is its bet that commercial-scale manufacture is solved ^[4]. Third, for business development, expect partnering terms for neoantigen platforms to harden once a Phase 3 proof point is on the board.

Verdict: high strategic threat to checkpoint-only adjuvant melanoma positioning, but the window stays open until the ESMO data put numbers to the benefit. Act on the readout, not the headline.